Recce Ltd announces advancement of pre-clinical toxicology and efficacy testing for lead compound

SYDNEY Australia, November 2, 2016: Recce Ltd (ASX: RCE) the developer of a new class of patented drugs targeted at antibiotic, anti-cancer and anti-viral human applications today announced preliminary results of some of the pre-clinical efficacy and toxicology studies currently underway for its lead synthetic anti-infective compound known as RECCE® 327.

Recce is compiling pre-clinical efficacy and toxicology data across several anti-bacterial, anti-cancer and anti-viral models as part of its planned Investigational New Drug (IND) application to the US Food & Drug Administration (FDA) in the first half of CY2017.

The pre-clinical studies are on track to be completed by April 2017.

Recce said an update provided by researchers noted a recent dose escalation study of its lead compound in a cancer mouse model indicated “treatment with RECCE® 327 was tolerated without animal deaths at both doses tested. It also noted “growth of the human HCT-116 colon carcinoma xenografts was not significantly inhibited by treatment with RECCE® 327 at either dose.”

Recce Executive Chairman Dr Graham Melrose said, “The data are encouraging and supports the continuation of the current test protocols. While there was no significant inhibition of growth in the cancer cells, the good toxicology data give us confidence to the dosing of our in vivo protocol for testing of RECCE® 327 activity in mice.”

For further information please visit www.recce.com.au or contact:

Investor Relations
Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: (08) 9253 9800

Media (Australia)
Andrew Geddes
CityPR
Tel: (02) 9267 4511

Media (International)
Sue Charles/Daniel Gooch
Instinctif Partners
Tel: +44 (0)20 7866 7905
E: recce@instinctif.com
About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.

The discovery of RECCE® 327’s capabilities against cancer and viruses (as well as bacteria-superbugs) has greatly increased the value of the Company’s technology, especially in view of the synergism between antibiotic/anti-cancer properties and anti-viral/anti-cancer properties.

Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies, and potential financial returns, from manufacture and distribution of its products in about 80% of the world’s pharmaceutical markets for antibiotics.

To receive the latest information on Recce - Subscribe here